Jrgensen H, Hill AS, Beste MT, Kumar MP, Chiswick E, Fedorcsak P, et al
The pricing is very affordable
References Brello Health Brello Health Review 2025: GLP-1 Telehealth Weight Loss Program With Semaglutide, Tirzepatide, and Personalized Coaching | Newswire Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction - PMC Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment - PMC Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity - PMC Brello Review: Digital Access to Compounded GLP-1 Medications - Sustainable Food Trade Association FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
While it is not a weight loss drug, diabetes patients on Ozempic may lose weight as a side effect because of the way the medication works
A comprehensive review of Bifidobacterium spp: as a probiotic, application in the food and therapeutic, and forthcoming trends